EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 184 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,565,709 | +25.7% | 99,284 | +54.9% | 0.00% | 0.0% |
| Q2 2023 | $1,245,793 | -14.5% | 64,084 | +24.7% | 0.00% | 0.0% |
| Q1 2023 | $1,457,594 | -26.4% | 51,378 | -24.2% | 0.00% | -33.3% |
| Q4 2022 | $1,981,444 | +14.7% | 67,788 | +3.7% | 0.00% | 0.0% |
| Q3 2022 | $1,727,000 | -45.4% | 65,378 | -8.1% | 0.00% | -40.0% |
| Q2 2022 | $3,161,000 | -46.4% | 71,138 | -40.3% | 0.01% | -37.5% |
| Q1 2022 | $5,898,000 | -14.7% | 119,173 | -12.2% | 0.01% | -11.1% |
| Q4 2021 | $6,913,000 | -34.1% | 135,736 | -27.8% | 0.01% | -40.0% |
| Q3 2021 | $10,485,000 | +38.2% | 188,002 | +6.1% | 0.02% | +50.0% |
| Q2 2021 | $7,587,000 | -14.2% | 177,251 | -16.3% | 0.01% | -23.1% |
| Q1 2021 | $8,839,000 | -19.6% | 211,743 | -10.3% | 0.01% | -27.8% |
| Q4 2020 | $10,998,000 | +17.0% | 236,158 | +6.7% | 0.02% | 0.0% |
| Q3 2020 | $9,402,000 | -8.2% | 221,327 | +3.6% | 0.02% | -10.0% |
| Q2 2020 | $10,247,000 | +89.7% | 213,564 | +81.9% | 0.02% | +66.7% |
| Q1 2020 | $5,401,000 | -24.9% | 117,421 | -1.9% | 0.01% | +9.1% |
| Q4 2019 | $7,191,000 | +41.6% | 119,694 | +33.3% | 0.01% | +37.5% |
| Q3 2019 | $5,079,000 | +55.9% | 89,780 | +53.4% | 0.01% | +60.0% |
| Q2 2019 | $3,258,000 | +18.0% | 58,523 | +7.0% | 0.01% | 0.0% |
| Q1 2019 | $2,762,000 | +108.3% | 54,706 | +66.3% | 0.01% | +150.0% |
| Q4 2018 | $1,326,000 | -24.4% | 32,897 | +30.1% | 0.00% | -33.3% |
| Q3 2018 | $1,754,000 | +37.2% | 25,292 | +49.8% | 0.00% | +50.0% |
| Q2 2018 | $1,278,000 | -87.6% | 16,888 | -91.4% | 0.00% | -87.5% |
| Q1 2018 | $10,321,000 | -52.0% | 195,882 | -51.3% | 0.02% | -44.8% |
| Q4 2017 | $21,481,000 | +62.2% | 402,122 | +81.1% | 0.03% | +52.6% |
| Q3 2017 | $13,244,000 | +586.9% | 222,072 | +808.7% | 0.02% | +533.3% |
| Q2 2017 | $1,928,000 | -8.0% | 24,438 | -3.3% | 0.00% | 0.0% |
| Q1 2017 | $2,096,000 | +65.7% | 25,274 | +58.5% | 0.00% | +50.0% |
| Q4 2016 | $1,265,000 | +23.4% | 15,944 | +8.9% | 0.00% | 0.0% |
| Q3 2016 | $1,025,000 | -63.7% | 14,640 | -54.1% | 0.00% | -60.0% |
| Q4 2015 | $2,826,000 | – | 31,870 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |